American depositary receipt

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Evolution AB (publ) Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EVVTY

Retrieved on: 
Friday, February 23, 2024

WHAT TO DO NEXT: To join the Evolution class action, go to https://rosenlegal.com/submit-form/?case_id=22119 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Evolution class action, go to https://rosenlegal.com/submit-form/?case_id=22119 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Gracell Biotechnologies Acquisition Completed

Retrieved on: 
Thursday, February 22, 2024

The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).

Key Points: 
  • The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).
  • As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent.
  • Such letters of transmittal must be completed before such holders can receive the applicable merger consideration.
  • Certificated ADS holders should wait to receive the letters of transmittal before surrendering their ADSs.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against British American Tobacco p.l.c. (BTI)

Retrieved on: 
Wednesday, February 21, 2024

LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired British American Tobacco p.l.c.

Key Points: 
  • LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired British American Tobacco p.l.c.
  • (“BAT” or the “Company”) (NYSE: BTI ) securities between February 9, 2023 and December 6, 2023, inclusive (the “Class Period”).
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

Retrieved on: 
Tuesday, February 20, 2024

The Company listed the ADSs on The Nasdaq Global Select Market in November 2017 under the ticker ERYP, and subsequently transferred the listing of its ADSs to The Nasdaq Capital Market in April 2023.

Key Points: 
  • The Company listed the ADSs on The Nasdaq Global Select Market in November 2017 under the ticker ERYP, and subsequently transferred the listing of its ADSs to The Nasdaq Capital Market in April 2023.
  • “Given PHAXIAM’s current stage of development, we have determined that delisting from the Nasdaq market was the wisest business and financial decision for the company.
  • PHAXIAM Therapeutics remains listed on Euronext Paris as its primary trading market and intends to continue its disclosures in compliance with applicable French financial market regulations.
  • Investors will receive either the underlying ordinary shares (if those have not yet been sold by the Depositary) or the cash received by the Depositary received upon sale of underlying ordinary shares, net of fees, if those underlying ordinary shares were sold.

TDCX Inc. Enters into Definitive Merger Agreement for Going-Private Transaction

Retrieved on: 
Friday, March 1, 2024

The Company’s board of directors (the “Board”), acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the “Special Committee”), approved the Merger Agreement and the Merger.

Key Points: 
  • The Company’s board of directors (the “Board”), acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the “Special Committee”), approved the Merger Agreement and the Merger.
  • The Special Committee negotiated the terms of the Merger Agreement with the assistance of its financial and legal advisors.
  • The Company will furnish to the U.S. Securities and Exchange Commission (the “SEC”) a current report on Form 6-K regarding the Merger, which will include as an exhibit thereto the Merger Agreement.
  • In connection with the Merger, the Company will prepare and mail a Schedule 13E-3 Transaction Statement (the “Schedule 13E-3”) to its shareholders.

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink

Retrieved on: 
Friday, March 1, 2024

The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink.

Key Points: 
  • The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink.
  • The Offer is now scheduled to expire at 5:00 p.m., New York time, on April 30, 2024, unless the Offer is extended or earlier terminated.
  • These Shares and ADSs collectively represent approximately 95.2% of the outstanding Shares as of such time.
  • Olink shareholders who have already tendered their Shares or ADSs of Olink do not have to re-tender their Shares or ADSs or take any other action as a result of the extension of the expiration time of the Offer.

Renesas Announces Termination of Memorandum of Understanding and Tender Offer for Proposed Acquisition of Sequans

Retrieved on: 
Friday, February 23, 2024

The previously announced tender offer has also been terminated by Renesas.

Key Points: 
  • The previously announced tender offer has also been terminated by Renesas.
  • As a result, Renesas exercised its right to terminate the MOU, and as a result of such termination, the tender offer has also been terminated.
  • As a result of the termination of the MOU and termination of the tender offer, no ordinary shares or ADSs of Sequans will be purchased by Renesas in the tender offer and all ordinary shares and ADSs previously tendered but not withdrawn will be promptly returned.
  • This communication constitutes a formal notification of the expiration of the tender offer and a formal notification that Renesas will not accept for purchase any ordinary shares or ADSs of Sequans tendered in connection with the tender offer.

Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in January

Retrieved on: 
Friday, February 23, 2024

The Fund estimates that it has distributed more than its net investment income and net realized capital gains; therefore, a portion of your distribution may be return of capital.

Key Points: 
  • The Fund estimates that it has distributed more than its net investment income and net realized capital gains; therefore, a portion of your distribution may be return of capital.
  • A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you.
  • A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income."
  • The amounts and sources of distributions reported above are only estimates and are not being provided for tax reporting purposes.

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Evolution AB (publ) Investors to Secure Counsel Before Important Deadline in Securities Class Action - EVVTY

Retrieved on: 
Sunday, March 10, 2024

WHAT TO DO NEXT: To join the Evolution class action, go to https://rosenlegal.com/submit-form/?case_id=22119 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Evolution class action, go to https://rosenlegal.com/submit-form/?case_id=22119 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Shareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with Akari

Retrieved on: 
Tuesday, March 5, 2024

MILWAUKEE, March 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Peak Bio (OTC: PKBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Akari.

Key Points: 
  • MILWAUKEE, March 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Peak Bio (OTC: PKBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Akari.
  • In the transaction, Peak Bio shareholders will receive only Peak Bio stockholders will receive a number of Akari ordinary shares (represented by American Depositary Shares) for each share of Peak stock they own, as determined on the basis of the exchange ratio described in the agreement.
  • The transaction agreement unreasonably limits competing transactions for Peak Bio by imposing a significant penalty if Peak Bio accepts a competing bid.
  • If you own Peak Bio common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/peak-bio-inc .